Immunofoco Biotechnology

Shanghai, China · Founded 2020 · In IPO Registration

Developer and manufacturer of CAR-T cell therapies and innovative treatment platforms designed for solid tumors and hematological cancers. Immunofoco Biotechnology is based in Shanghai, China and was founded in 2020. Its last reported valuation was $298 million in Feb 2026. It has raised $139 million.

Last reported valuation
$298.1M
Oct 2026
Priced at
—
Total raised
$138.8M
Last round
—

Who backs Immunofoco Biotechnology?

27 investors
The directory is free. Investor activity — the working column — is Pro.Unlock prospecting columns

Membership and data by Private Market View

Immunofoco Biotechnology investors

27 investors are on record for Immunofoco Biotechnology, including ZhenFund, Green Pine Capital Partners, Shenzhen Nanshan Strategic Emerging Industry Investment and Orinno Capital. By type, the record holds 5 venture capital firms.

Free account
More of Immunofoco Biotechnology with a free account
  • ·The complete investor list: 27 names
  • ·Watch Immunofoco Biotechnology: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

For fundraisers
Work this list, don’t just read it

These 27 firms already write checks for companies like Immunofoco Biotechnology. Build the wider list: every firm that has backed a company like this one, ranked by how often and how recently.

Find investors like these →

Membership and data by Private Market View